The Effects of Combination Therapy Utilizing Calcium Disodium EDTA Suppositories and Tetracycline for the Treatment of Prostatitis and Prostate Calcification

AN ON-LINE CONTINUATION STUDY

Background
The incidence of prostate conditions such as benign prostatic hypertrophy (BPH), is at least 50 percent for all men at the age of 50. It rises to almost 90 percent of all men in their eighth decade of life. A man's risk of developing prostate cancer is related to his age, genetics, race, diet, lifestyle, medications, and other factors. The primary risk factor is age because prostate cancer becomes more common with advancing age.

Based on encouraging results of an initial pilot study,conducted in Tustin, California, under the direction of Dr. Rita Ellithorpe, a new, expanded study has been launched. Using the same clinical protocol, this new study is examining the effects of an EDTA chelation suppository, called Detoxamin, and an antibiotic, (tetracycline) to reduce or eliminate prostate calcifications and the symptoms associated with this condition. This study has recently received full investigational review Board (IRB) approval.

The prostate research team is optimistic about their experiences and outcomes with combination detoxification therapy. In addition, published clinical studies show chelation therapy can effectively remove heavy metal toxin buildup (heavy metal toxicity can cause a variety of serious clinical conditions) and dissolve calcium deposits within the body. Further research demonstrates that nanobacteria lodge in the prostate and form protective coverings and calcifications (similar to kidney stones). The calcifications increase in number and size over time and cause a variety of symptoms, which can lead to debilitating disease. The treatments set forward in this study have a high probability of addressing the purported cause of this prostate condition.

Study Goals
This 90-day study will utilize a safe proprietary protocol to help reduce signs and symptoms of prostatitis, prostate calcifications, BPH and other health challenges caused by toxic buildup and infectious agents called nanobacteria.

Brief Protocol
Participants in this study will be required to take a combination of the EDTA suppository (Detoxamin), tetracycline, vitamin/mineral supplements and a probiotic. There are online symptom surveys that are to be filled out to evaluate treatment results. Participants will also be able to choose ultrasonography (ultrasound diagnosis) and fecal heavy metal analysis tests before and after treatment.

"I encourage you to log onto www.prostate90study.com or call the research clinic at 714-544-1521 to find out more about this important study. Perhaps you or your loved ones may experience improved health benefits with participation."

Rita Ellithorpe, M.D.

To enroll go to www.prostate90study.com